About Us
Board of Directors
Michael J. Coyle
Michael J. Coyle was appointed to the Board of Directors in April 2009. From 2001 through December 31, 2007, he was president of the Cardiac Rhythm Management Division of St. Jude Medical, Inc., a medical device company specializing in the development and manufacturing of cardiovascular devices. Mr. Coyle joined St. Jude Medical as director of Business Development in 1994 and was appointed president of the Daig Division, a specialty catheter business, in 1997. Previously, Mr. Coyle spent nine years in business and technical management positions in the medical device and pharmaceutical divisions of Eli Lilly & Company. Mr. Coyle has been a Director of VNUS Medical Technologies, Inc., a publicly traded medical device company, since 1995. He holds a B.S. in Chemical Engineering from Case Western Reserve University and an M.B.A. from the Wharton School of the University of Pennsylvania.
Kieran T. Gallahue was appointed to the Board of Directors in July 2007. Mr. Gallahue is the Chairman and CEO of CareFusion. Previously, Mr. Gallahue has served as President (ResMed Global) of ResMed Inc., a developer, manufacturer and marketer of products for the treatment of sleep-disordered breathing and other respiratory disorders. From January 2003 to September 2004, Mr. Gallahue served as President and Chief Operating Officer (ResMed Americas) of ResMed Inc. From [1995] to January 2003, Mr. Gallahue served in various capacities with Nanogen, Inc., a San Diego-based DNA research and medical diagnostics company, including as President, Chief Financial Officer and Vice President of Strategic Marketing. From 1995 to 1997, he served as Vice President of the Critical Care Business Unit for Instrumentation Laboratory, where he was responsible for worldwide strategic sales and marketing, and research and development efforts for this business unit. From 1992 to 1995, he held a variety of sales and marketing positions within Instrumentation Laboratory. In addition, Mr. Gallahue held various marketing and financial positions within Procter & Gamble and the General Electric Company. Mr. Gallahue holds a B.A. from Rutgers University and an M.B.A. from Harvard Business School.
Lesley H. Howe was appointed to the Board of Directors in October 2005. Since December 2001, he has served as Chief Executive Officer at Consumer Networks LLC, an Internet marketing and promotions company. Mr. Howe currently serves on the Board of Directors of dj Orthopedics, Inc., a medical technology company, P.F. Chang's China Bistro, Inc., an owner and operator of restaurants, and NuVasive, Inc., a medical technology company. From July 1967 to September 1997, Mr. Howe held several positions at KPMG Peat Marwick LLP, an international auditing and accounting firm, and served as area managing partner/managing partner of their Los Angeles office from May 1994 to September 1997. Mr. Howe holds a B.S. in Accounting from the University of Arkansas and is a certified public accountant.
Scott Huennekens has served as President and Chief Executive Officer since April 2002. From January 2000 to March 2002, he served as the President and Chief Executive Officer of Digirad Corporation, a medical imaging company. Mr. Huennekens is a member of the Board of Directors for Volcano Corporation, Uptake Medical, the Medical Device Manufacturers Association (MDMA), and BIOCOM. He received a B.S. in Business Administration from the University of Southern California and an M.B.A. from Harvard Business School.
Alexis V. Lukianov was appointed to the Board of Directors in December 2007. Since July 1999, Mr. Lukianov has served NuVasive, Inc as its President, Chief Executive Officer and a director, and since February 2004, Mr. Lukianov has served as Chairman of the Board and Chief Executive Officer. NuVasive, Inc. is a publicly-traded medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. From April 1996 to April 1997, Mr. Lukianov was a founder of and served as Chairman of the Board and Chief Executive Officer of BackCare Group, Inc., a spine physician practice management company. From January 1990 to October 1995, Mr. Lukianov held a variety of senior executive positions including president with Medtronic Sofamor Danek, Inc., a developer and manufacturer of medical devices to treat disorders of the cranium and spine, and a subsidiary of Medtronic, Inc., a publicly-traded medical technology company. Mr. Lukianov has over 20 years of successful experience in the orthopedic industry including various positions with the orthopedics division of Smith and Nephew and also a joint venture between Meadox Medicals, Inc. (Boston Scientific) and Stryker Corporation orthopedics. Mr. Lukianov serves on the boards of NuVasive, Inc., California Health Institute, BIOCOM, Medical Device Manufacturers Association and Ophthonix, Inc., a privately-held company focused on vision correction technology.
Ronald A. Matricaria was appointed to the Board of Directors in October 2005. He served as Chairman of St. Jude Medical, Inc. from January 1995 to December 2002, and as President and Chief Executive Officer from April 1993 to May 1999. Mr. Matricaria currently serves on the boards of directors of Life Technologies Corporation, a life sciences company and Hospira, Inc., a specialty pharmaceuticals company. He is also Trustee emeritus of the University of Minnesota Foundation. Mr. Matricaria holds a bachelor's degree from the Massachusetts College of Pharmacy and was awarded an honorary doctorate degree in Pharmacy in recognition of his contribution to the practice of pharmacy.
Leslie Norwalk is Strategic Counsel to Epstein Becker & Green, P.C., EBG Advisors and National Health Advisors. She serves as an advisor to three private equity firms: Warburg Pincus, Ferrer Freeman & Company, and Enhanced Equity Fund, and sits on the boards of directors of Sound Physicians, Guardian Healthcare Group, Sante Pediatric Rehabilitation, IkaSystems, MTS Medication Technologies, InHealth, Press Ganey, and the International Advisory Board of APCO Worldwide.
Ms. Norwalk served the Bush Administration as the Acting Administrator for the Centers for Medicare & Medicaid Services (CMS). She managed the day-to-day operations of Medicare, Medicaid, State Child Health Insurance Programs, Survey and Certification of health care facilities and other federal health care initiatives. For four years prior to that, she was the agency's Deputy Administrator, responsible for the implementation of the hundreds of changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit. CMS has the second-largest budget outlay of the Federal Government, directly responsible for $1 out of every $3 spent on healthcare in the United States. The organization insures nearly a third of the population of the United States (more than 95 million beneficiaries) including the elderly, disabled, and some of the lowest income individuals in the country. CMS processes over one billion claims each year and contracts with approximately one million providers.
Prior to serving the Bush Administration, she practiced law in the Washington, D.C. office of Epstein Becker & Green, P.C. where she advised clients on a variety of health policy matters. She also served in the first Bush administration in the White House Office of Presidential Personnel, and the Office of the U.S. Trade Representative.
Ms. Norwalk, a native of Dayton, OH, earned a juris doctor degree from the George Mason University School of Law, where she was a Dean's Scholar and an editor of the George Mason Law Review. She earned a bachelor's degree, cum laude, in economics and international relations from Wellesley College.
Ms. Norwalk served the Bush Administration as the Acting Administrator for the Centers for Medicare & Medicaid Services (CMS). She managed the day-to-day operations of Medicare, Medicaid, State Child Health Insurance Programs, Survey and Certification of health care facilities and other federal health care initiatives. For four years prior to that, she was the agency's Deputy Administrator, responsible for the implementation of the hundreds of changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit. CMS has the second-largest budget outlay of the Federal Government, directly responsible for $1 out of every $3 spent on healthcare in the United States. The organization insures nearly a third of the population of the United States (more than 95 million beneficiaries) including the elderly, disabled, and some of the lowest income individuals in the country. CMS processes over one billion claims each year and contracts with approximately one million providers.
Prior to serving the Bush Administration, she practiced law in the Washington, D.C. office of Epstein Becker & Green, P.C. where she advised clients on a variety of health policy matters. She also served in the first Bush administration in the White House Office of Presidential Personnel, and the Office of the U.S. Trade Representative.
Ms. Norwalk, a native of Dayton, OH, earned a juris doctor degree from the George Mason University School of Law, where she was a Dean's Scholar and an editor of the George Mason Law Review. She earned a bachelor's degree, cum laude, in economics and international relations from Wellesley College.
John Onopchenko rejoined the Board of Directors in June 2007. He is a founder and Managing Director of Synergy Life Science Partners, L.P., a venture capital firm. From 2000 to 2006, Mr. Onopchenko was Vice President, Venture Investments, with Johnson & Johnson Development Corporation, and served as a member of our board of directors from 2002 to 2006. From 1996 to 1999, he served as Vice President and a member of the board of directors of Advanced Sterilization Products, a division of Johnson & Johnson.
Mr. Onopchenko serves on the boards of directors of various private companies in the healthcare and life sciences industry.
Mr. Onopchenko holds a masters degree in Business from the University of Chicago, Graduate School of Business and a bachelors of Science degree from Ursinus College.
Mr. Onopchenko serves on the boards of directors of various private companies in the healthcare and life sciences industry.
Mr. Onopchenko holds a masters degree in Business from the University of Chicago, Graduate School of Business and a bachelors of Science degree from Ursinus College.
Roy T. Tanaka was appointed to the Board of Directors in April 2009. From 2004 through 2008, Mr. Tanaka served as the Worldwide President of Biosense Webster, Inc. for Johnson & Johnson. Mr. Tanaka joined Johnson & Johnson as the U.S. President of Biosense Webster, Inc. in 1997. From 1992 to 1997, he served in a variety of senior management positions at Sorin Biomedical, Inc., including President and Chief Executive Officer. From 1989 to 1992, Mr. Tanaka served in Vice President roles with Shiley, a division of Pfizer Inc. Mr. Tanaka received a B.S. in Mechanical Engineering from Purdue University and an M.B.A. from Illinois Benedictine College.
Dr. Topol is a pioneer of the genomic and wireless digital innovative technologies to reshape the future of medicine.
He is a practicing cardiologist at Scripps in La Jolla, California and well known for leading the Cleveland Clinic to become the #1 center for heart care. While there he also started a new medical school, led many worldwide clinical trials to advance care for patients with heart disease, and spearheaded the discovery of multiple genes that increase susceptibility for heart attacks.
Since 2006, in La Jolla, he leads the flagship NIH supported Scripps Translational Science Institute and is a co-Founder and the Vice-Chairman of the West Wireless Health Institute. He also serves as Professor of Genomics at The Scripps Research Institute and Chief Academic Officer of Scripps Health.
Topol pioneered the development of many medications that are routinely used in medical practice including t-PA, Plavix, Angiomax, and ReoPro and was the first physician to raise safety concerns on Vioxx. He has published 1100 peer-reviewed articles and over 30 medical textbooks. In 2009, along with Francis Collins and Harold Varmus, Topol was selected to be one of the country’s 12 “Rock Stars of Science” in GQ Magazine . In 2011, the University of Michigan, where he had served on the faculty, initiated the Eric Topol Professor of Cardiovascular Medicine to recognize his contributions. The University of Rochester, his alma mater medical school, awarded him the Hutchinson Medal, the University’s highest honor.
He was named as one of the Top 100 Most Influential People in Healthcare in 2011.
He was elected to the Institute of Medicine of the National Academy of Sciences and is one of the top 10 most cited researchers in medicine. His book The Creative Destruction of Medicine (Basic Books) was published in 2012.
He is a practicing cardiologist at Scripps in La Jolla, California and well known for leading the Cleveland Clinic to become the #1 center for heart care. While there he also started a new medical school, led many worldwide clinical trials to advance care for patients with heart disease, and spearheaded the discovery of multiple genes that increase susceptibility for heart attacks.
Since 2006, in La Jolla, he leads the flagship NIH supported Scripps Translational Science Institute and is a co-Founder and the Vice-Chairman of the West Wireless Health Institute. He also serves as Professor of Genomics at The Scripps Research Institute and Chief Academic Officer of Scripps Health.
Topol pioneered the development of many medications that are routinely used in medical practice including t-PA, Plavix, Angiomax, and ReoPro and was the first physician to raise safety concerns on Vioxx. He has published 1100 peer-reviewed articles and over 30 medical textbooks. In 2009, along with Francis Collins and Harold Varmus, Topol was selected to be one of the country’s 12 “Rock Stars of Science” in GQ Magazine . In 2011, the University of Michigan, where he had served on the faculty, initiated the Eric Topol Professor of Cardiovascular Medicine to recognize his contributions. The University of Rochester, his alma mater medical school, awarded him the Hutchinson Medal, the University’s highest honor.
He was named as one of the Top 100 Most Influential People in Healthcare in 2011.
He was elected to the Institute of Medicine of the National Academy of Sciences and is one of the top 10 most cited researchers in medicine. His book The Creative Destruction of Medicine (Basic Books) was published in 2012.